pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
RZOLV Reports Approximately 97.0% Gold Recovery on Complex Copper-Gold Ore Without Pretreatment, Highlighting Potential to Simplify Flowsheets Versus Cyanide
RZOLV Reports Approximately 97.0% Gold Recovery on Complex Copper-Gold Ore Without Pretreatment, Highlighting Potential to Simplify Flowsheets Versus Cyanide
